Moon Eun-Sang – CEO, SillaJen – South Korea
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
SillaJen, Inc. is a privately-held biotechnology company focusing on engineering and developing best-in-class oncolytic immunotherapeutics. SillaJen has Korean offices in Busan (R&D), at Pusan National University (PNU), and in Seoul (finance, management & legal). SillaJen also has Clinical R&D, regulatory affairs and CMC capabilities in San Francisco, California, one of the world’s leading biotechnology centers and the “birthplace” of the biotech industry. SillaJen products are engineered from vaccinia which has unique attributes as an oncolytic immunotherapy.
Contact Details
Busan Office
Seoul Office
San Francisco Office
SillaJen’s CEO shares his passion for his companies oncolytic vaccinia virus, and its potential to revolutionize the treatment of solid tumor cancers, even arguing that it may eventually constitute ‘a…
Song In-Keum, chairman of the Korean Medical Devices Industry Association (KMDIA), discusses current opportunities offered by Korea’s growing medtech industry. What have been your priorities since you became the…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
The director general of Korea’s Bureau of Health Industry explains what has led to Korea’s excellent healthcare system, and the competitiveness of the country’s pharmaceutical sector. Can you provide our…
Jung Kee-Taig, president of the Korea Health Industry Development Institute (KHIDI), outlines his “Health Economy 2030” for Korea, and highlights the institute’s domestic and international collaborations. KHIDI aims to…
Prior to founding Bioneer, Park Han-Oh spent a number of years working at KRIBB. Today he speaks about the company’s latest breakthrough technology in DNA synthesis and his outlook for…
See our Cookie Privacy Policy Here
